RESUMO
Magnetic nanocomposites were synthesized for the targeted delivery of hydrophilic bioactives through guidance generated by a magnetic field. Superparamagnetic iron oxide nanoparticles (SPIONs) were used to generate hydroxyethyl starch magnetic nanocapsules (HES MNCs). This synthesis allowed the co-encapsulation of oncocalyxone A (onco A) and surface-modified magnetite nanoparticles (Fe3O4@citrate) into the same nanostructure. The synthesized nanocapsules exhibited a core-shell morphology, with an average diameter of 143â¯nm. This nanocomposite showed potential anticancer activity (IC50) against four human tumor cell lines: glioblastoma SNB-19 (1.010 µgmL-1), colon carcinoma HCT-116 (2.675 µgmL-1), prostate PC3 (4.868 µgmL-1), and leukemia HL-60 (2.166 µgmL-1). Additionally, in vivo toxicity and locomotor activity were evaluated in a zebrafish (Danio rerio) model. The nanocomposite exhibited in vitro cytotoxicity, prolonged drug release profile and also responded to an applied magnetic field, representing a versatile compound with perspectives for highest concentration of different hydrophilic bioactives in a target tissue through magnetic vectorization.
Assuntos
Antraquinonas/farmacologia , Sistemas de Liberação de Medicamentos/métodos , Nanopartículas Magnéticas de Óxido de Ferro/química , Nanocompostos/química , Neoplasias/tratamento farmacológico , Amido/química , Animais , Antraquinonas/química , Linhagem Celular Tumoral , Portadores de Fármacos/química , Portadores de Fármacos/farmacologia , Liberação Controlada de Fármacos , Glioblastoma/tratamento farmacológico , Glioblastoma/patologia , Humanos , Interações Hidrofóbicas e Hidrofílicas , Campos Magnéticos , Masculino , Nanocápsulas/química , Neoplasias/patologia , Peixe-ZebraRESUMO
This work proposes the development of a starch-based drug carrier for fluoxetine (FLX) delivery and evaluate the improvement of the drug antibacterial activity. The starch nanocapsules were prepared via interfacial polyaddition reaction presenting a core-shell morphology, based on polyurethane linkage, with a particle size in the range 250-300 nm. Furthermore, FLX-loaded nanocapsules were evaluated regarding antibacterial potential against Staphylococcus aureus (ATCC® 6538P ™) and its clinical strains of methicillin-resistant. As expected, the FLX-loaded presented lower minimum inhibitory concentration (MIC) values, in the range of 190-95 µg mL-1, against all isolated microorganisms in comparison to FLX, 255 µg mL-1. According to results, the FLX-loaded starch nanocapsules have successfully improved drug antibacterial activity, generating promising perspectives on the field of the hydrophilic drug delivery systems.